News Releases

 

BioSante Pharmaceuticals to Discuss LibiGel® SPA in the Treatment of FSD, at BIO CEO and Investor Conference

Lincolnshire, Illinois (February 06, 2008) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO will discuss BioSante’s recently granted special protocol assessment (SPA) for the Phase III development of LibiGel (testosterone gel) in the treatment of female sexual dysfunction (FSD), at the BIO CEO and Investor Conference at the Waldorf Astoria in New York City. Mr. Simes will present on February 11, 2008 at 2:45 p.m. local time. A corporate update and overview also will be presented.

The BIO conference provides a forum for institutional investors, industry analysts, and senior biotechnology executives to have the opportunity to shape the future investment landscape of the biotechnology industry.

A live audio webcast of BioSante’s presentation at the BIO conference may be accessed at biosantepharma.cdmail.biz/Webcasts.php and a replay will be available at the same link for 90 days.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver estradiol and testosterone. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under an FDA SPA for the treatment of female sexual dysfunction (FSD) and Elestrin& (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante’s licensee. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.

###

For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220
azachary@harrisdmckinney.com